HealthCor Management

HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.

Karyopharm Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Newton, Massachusetts, specializing in the discovery, development, and commercialization of novel drugs targeting nuclear export mechanisms for the treatment of cancer and other diseases. Its lead drug, XPOVIO (selinexor), is an approved treatment for multiple hematologic malignancies, particularly in patients with heavily pretreated multiple myeloma. The company is advancing several clinical trials for its products, including BOSTON and STORM for multiple myeloma, SADAL for relapsed or refractory diffuse large B-cell lymphoma, and SEAL for liposarcoma. Karyopharm is also exploring treatments for endometrial cancer and glioblastoma multiforme. Additionally, the company has partnerships to investigate low-dose selinexor for hospitalized COVID-19 patients and collaborates with the National Cancer Institute for cancer therapy evaluations. Karyopharm utilizes a proprietary platform to develop small molecule drugs that modulate key cellular pathways involved in cancer and inflammation.

Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.

Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery.

Ikena Oncology is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for cancer treatment. The company specializes in biomarker-driven and precision therapies that target specific mechanisms involved in cancer growth, spread, and resistance. Its product pipeline includes several candidates such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-930, an oral small-molecule inhibitor of the TEAD transcription factor in the Hippo signaling pathway. Additionally, Ikena is exploring a kynurenine-degrading enzyme with IK-412 and other discovery-stage programs targeting various oncogenic pathways. Established in 2016, Ikena Oncology aims to address unmet medical needs through a combination of chemistry, translational science, and patient-centered drug development.

Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.

Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.

PreemaTEX is the developer of an innovative, high value diagnostic tests focused on assessing a woman’s risk for preterm delivery early in pregnancy.

ReShape Medical Inc. specializes in non-surgical weight loss solutions aimed at individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30 to 40. The company offers the ReShape Integrated Dual Balloon System, which consists of two intragastric balloons that are placed in the stomach and filled with saline. This system is intended to assist patients in losing weight when combined with a medically supervised diet and exercise program. The procedure is designed for adults who have not achieved significant weight loss through diet and exercise alone. ReShape Medical also provides other weight management solutions, including the FDA-approved Lap-Band System and the investigational ReShape Vest System, which aim to support patients in their weight loss journeys while minimizing the need for invasive surgical procedures. Founded in 2005 and based in San Clemente, California, ReShape Medical operates as a subsidiary of EnteroMedics Inc.

HLS Therapeutics Inc is a specialty pharmaceutical company focused on the acquisition and commercialization of branded pharmaceutical products in North America. The company is dedicated to managing the life cycles of these products after exclusivity, ensuring the availability of essential treatments for patients and caregivers. HLS's portfolio includes notable products such as Clozaril, Vascepa, and CSAN Pronto. The majority of the company's revenue is generated through product sales, supplemented by royalties. HLS operates primarily in Canada and the United States, as well as in other international markets.

Natera, Inc. is a diagnostic company that specializes in preconception and prenatal genetic testing services. Its primary offerings include the Panorama test, which is a non-invasive prenatal test that screens for chromosomal abnormalities in a fetus through a blood sample from the mother, and the Vistara test, designed to identify single-gene disorders. Additionally, Natera provides Horizon carrier screening to determine genetic disease carrier status and Spectrum, which analyzes chromosomal anomalies during in vitro fertilization. The company also offers Anora, a test for analyzing fetal chromosomes to investigate miscarriage causes, and non-invasive paternity testing. Its Signatera product utilizes circulating tumor DNA technology to monitor cancer recurrence. Natera markets its tests through a direct sales force and a network of approximately 100 laboratory and distribution partners both domestically and internationally. The company, founded in 2003 and headquartered in San Carlos, California, maintains partnerships with BGI Genomics and Foundation Medicine for the development of genetic testing assays.

CareView Communications develops a proprietary network system that can be deployed throughout a healthcare facility using the existing coaxial cable infrastructure and provides a suite of software applications designed to reduce patient falls, streamline workflow and improve HCAHPS scores. Real-time patient monitoring enhances safety and security while Virtual Bed Rails (R) and Virtual Chair Rails (R) prevent falls BEFORE they happen. The bed management program provides a real-time dashboard of bed status of all hospital beds, for patient placement and the prevention of overcrowding. CareView Mobile is a point-of-care application that allows nursing to see, communicate with and manage patients from the palm of their hand. Voice (VoIP), text and email capability allow staff members to communicate with ease and efficiency. A guest services package provides a suite of entertainment features to increase patient satisfaction and the overall hospital experience and a patient education portal provides convenient, click-of-a-button access to a collection of education, to inform and educate the patient and their family.

Sadra Medical is focused on developing innovative therapies for the treatment of aortic valve disease, particularly through minimally invasive alternatives to traditional surgical valve replacement. The company offers transcatheter aortic valve replacement systems, including the Lotus valve, which is a bovine tissue tri-leaflet bioprosthetic aortic valve supported by a nitinol stent structure. Additionally, Sadra Medical provides the Lotus delivery catheter, designed for the guidance and placement of the Lotus valve. With aortic valve stenosis affecting approximately 3 million people in the U.S. and a significant portion remaining untreated, Sadra Medical aims to address this unmet clinical need by enhancing treatment options and improving patient care while reducing the risks associated with open-heart surgery.

ApaTech Ltd. is an ortho-biologics company based in Elstree, United Kingdom, specializing in synthetic bone repair materials for surgical applications. Founded in 2001, the company develops innovative products such as Actifuse, a synthetic bone graft that enhances bone formation and is particularly effective for small void filling and spinal fusion. Additionally, ApaTech offers ApaPore, a porous hydroxyapatite grafting solution designed for the revision of failed total joint arthroplasties and the treatment of bone defects. The Actifuse MIS Bone Graft Delivery System provides precise delivery and placement for a range of surgical procedures, including open and minimally invasive operations. ApaTech distributes its products through a network of partners across multiple countries, including those in Europe and Australia. The company also maintains operations in London, Foxborough, Massachusetts, and Berlin, Germany.

Corindus designs, manufactures, and commercializes remote robotic systems for interventional procedures. The company's products include CorPath, which enables physicians to perform catheterization procedures from a remote location away from the radiation zone. The company was formerly known as Navicath, Ltd. Corindus was founded in 2002 and is based in Waltham, Massachusetts.

HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.

Paradigm Spine, LLC is a privately-held medical device company based in New York, specializing in the design, development, and marketing of innovative solutions for spinal diseases. The company focuses on non-fusion spinal implant technology, offering a range of minimally invasive products aimed at treating conditions such as lumbar spinal stenosis and age-related spinal deformities. Key offerings include the Coflex interspinous implant, which is used for facet arthrosis and decompression procedures, as well as the DSS system, a minimally-invasive pedicle-screw based solution. Paradigm Spine emphasizes the development of surgeon-centric and indication-specific products that preserve motion and support natural anatomical function, catering to spine specialists worldwide. Founded in 2002, the company was previously known as Spine Motion, LLC before rebranding in 2005.